GB201807050D0 - Medical uses - Google Patents

Medical uses

Info

Publication number
GB201807050D0
GB201807050D0 GBGB1807050.8A GB201807050A GB201807050D0 GB 201807050 D0 GB201807050 D0 GB 201807050D0 GB 201807050 A GB201807050 A GB 201807050A GB 201807050 D0 GB201807050 D0 GB 201807050D0
Authority
GB
United Kingdom
Prior art keywords
medical uses
medical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1807050.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellprotect Nordic Pharmaceuticals AB
Original Assignee
Cellprotect Nordic Pharmaceuticals AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellprotect Nordic Pharmaceuticals AB filed Critical Cellprotect Nordic Pharmaceuticals AB
Priority to GBGB1807050.8A priority Critical patent/GB201807050D0/en
Publication of GB201807050D0 publication Critical patent/GB201807050D0/en
Priority to JP2021510533A priority patent/JP2022522914A/ja
Priority to AU2019264457A priority patent/AU2019264457B2/en
Priority to BR112020022062-0A priority patent/BR112020022062A2/pt
Priority to KR1020207034431A priority patent/KR102908831B1/ko
Priority to US17/048,702 priority patent/US20210186977A1/en
Priority to PCT/EP2019/061122 priority patent/WO2019211310A1/en
Priority to EP19722058.5A priority patent/EP3787685A1/en
Priority to CA3097379A priority patent/CA3097379A1/en
Priority to CN201980029357.3A priority patent/CN112399858A/zh
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1807050.8A 2018-04-30 2018-04-30 Medical uses Ceased GB201807050D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB1807050.8A GB201807050D0 (en) 2018-04-30 2018-04-30 Medical uses
CN201980029357.3A CN112399858A (zh) 2018-04-30 2019-04-30 医学用途
KR1020207034431A KR102908831B1 (ko) 2018-04-30 2019-04-30 의학 용도
AU2019264457A AU2019264457B2 (en) 2018-04-30 2019-04-30 Medical uses
BR112020022062-0A BR112020022062A2 (pt) 2018-04-30 2019-04-30 usos médicos
JP2021510533A JP2022522914A (ja) 2018-04-30 2019-04-30 医学的使用
US17/048,702 US20210186977A1 (en) 2018-04-30 2019-04-30 Medical uses
PCT/EP2019/061122 WO2019211310A1 (en) 2018-04-30 2019-04-30 Medical uses
EP19722058.5A EP3787685A1 (en) 2018-04-30 2019-04-30 Medical uses
CA3097379A CA3097379A1 (en) 2018-04-30 2019-04-30 Nk cell combination therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1807050.8A GB201807050D0 (en) 2018-04-30 2018-04-30 Medical uses

Publications (1)

Publication Number Publication Date
GB201807050D0 true GB201807050D0 (en) 2018-06-13

Family

ID=62494975

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1807050.8A Ceased GB201807050D0 (en) 2018-04-30 2018-04-30 Medical uses

Country Status (10)

Country Link
US (1) US20210186977A1 (https=)
EP (1) EP3787685A1 (https=)
JP (1) JP2022522914A (https=)
KR (1) KR102908831B1 (https=)
CN (1) CN112399858A (https=)
AU (1) AU2019264457B2 (https=)
BR (1) BR112020022062A2 (https=)
CA (1) CA3097379A1 (https=)
GB (1) GB201807050D0 (https=)
WO (1) WO2019211310A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112168829B (zh) * 2020-09-24 2022-02-15 华南理工大学 抗病毒药物在制备治疗骨髓增生异常综合征药物中的应用及制得的骨髓增生异常综合征药物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007016450A2 (en) * 2005-07-29 2007-02-08 Beth Israel Deaconess Medical Center Methods for treating or preventing reactivation of a latent herpesvirus infection
CN101506154B (zh) * 2006-08-21 2015-06-17 辛塔制药公司 用于治疗增生性疾病的化合物
US20090123442A1 (en) * 2007-11-09 2009-05-14 Avaris Ab Expanded nk cells
US8877182B2 (en) * 2009-03-26 2014-11-04 Cellprotect Nordic Pharmaceuticals Ab Expansion of NK cells
US20130011376A1 (en) * 2009-12-29 2013-01-10 Gamida Cell Ltd. Methods for Enhancing Natural Killer Cell Proliferation and Activity
JP5989016B2 (ja) * 2011-06-24 2016-09-07 国立大学法人九州大学 Ｎｋ細胞の増幅方法
JP6501264B2 (ja) * 2012-07-24 2019-04-17 アヴァリン ファーマ インク． エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
US20180021378A1 (en) * 2014-12-31 2018-01-25 Anthrogenesis Corporation Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
KR102416781B1 (ko) * 2015-08-20 2022-07-05 고려대학교 산학협력단 수두 대상포진 바이러스에 의해 유발되는 질병의 치료 또는 예방용 약학 조성물

Also Published As

Publication number Publication date
AU2019264457A1 (en) 2020-11-12
CN112399858A (zh) 2021-02-23
AU2019264457B2 (en) 2025-02-20
EP3787685A1 (en) 2021-03-10
JP2022522914A (ja) 2022-04-21
BR112020022062A2 (pt) 2021-02-02
WO2019211310A1 (en) 2019-11-07
KR20210002690A (ko) 2021-01-08
CA3097379A1 (en) 2019-11-07
KR102908831B1 (ko) 2026-01-06
US20210186977A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
IL267995A (en) Medical team
IL274108A (en) medical system
GB2563578B (en) Medical devices
CA186425S (en) Catheter
GB201813876D0 (en) Treatment
SG11202008100UA (en) Patient interface
GB201813986D0 (en) Coffins
GB201819164D0 (en) Artificial-intelligence-assisted surgery
SG11202106667YA (en) Skin-mountable medical device
GB201804090D0 (en) Medical device
GB201800546D0 (en) Treatment
PL3773400T3 (pl) Wózek inwalidzki
CA184871S (en) Medical device
GB201810749D0 (en) Endoscope
GB201701438D0 (en) Skine tissue
SG10201907154QA (en) Cannula
GB201807050D0 (en) Medical uses
CA187131S (en) Casket
CA186424S (en) Catheter
GB2581623B (en) Wheelchair
PL3727125T3 (pl) Endoskop
GB201717924D0 (en) Medical devices
GB201813217D0 (en) New medical uses
GB201810643D0 (en) New medical uses
GB2573210B (en) Casket

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)